Vnitr Lek 2022, 68(3):195-196 | DOI: 10.36290/vnl.2022.039

What connects SGLT2 inhibitors, diabetes mellitus, heart failure and empagliflozin?

Richard Češka
Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha

Published: April 26, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češka R. What connects SGLT2 inhibitors, diabetes mellitus, heart failure and empagliflozin? Vnitr Lek. 2022;68(3):195-196. doi: 10.36290/vnl.2022.039.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3599-3726, https://doi.org/10.1093/eurheartj/ehab368 Go to original source... Go to PubMed...
    2. McGill JB. The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: a bench to bedside review. Diabetes Ther. 2014;5(1):43-63. doi: 10.1007/ s13300-014-0063 Go to original source...
    3. Braunwald E. The war against heart failure. Lancet. 2015;385(9970):812-824. doi: 10.1016/ S0140-6736(14)61889-4. Go to original source... Go to PubMed...
    4. Zinman B, Wanner CH, Lachin JM et al. The EMPA‑REG OUTCOME investigators: empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi: 10.1056/ NEJMoa1504720. Go to original source... Go to PubMed...
    5. Anker SD, Butler J, Filippatos G et al. For the EMPEROR‑Preserved Trial Investigators: Empagliflozin in Heart Failure with a Preserved Ejection Fraction, N Engl J Med. 2021;385:1451-1461,DOI: 10.1056/NEJMoa2107038 Go to original source... Go to PubMed...
    6. Šoupal J, Prázný M. Postavení nových antidiabetik v klinické praxi: SGLT2 vs DPP4 inhibitory. Vnitř Lék. 2015;61(4):291-294. Go to PubMed...
    7. Kvapil M. EMPA REG OUTCOME. Důkaz, že populace pacientů s diabetem se mění. Remedia 2016;26(1):67-72.
    8. Vítovec J, Špinar J, Špinarová L. Empagliflozin a srdeční selhání. Hypertenze a KV prevence. 2016;5(2):19-23.
    9. Sattar N, Petrie MC, Zinnad B et al. Novel diabetes drugs and the cardiovascular specialist. J Am Coll Cardiol. 2017;69(21):2646-2656. doi: 10.1016/ j.jacc.2017. 04. 014. Go to original source...
    10. Kosiborod M, Cavender MA, Fu AZ et al. The CVD‑REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose‑lowering drugs. Circulation 2017;136(3):249-259. doi: 10.1161/ CIRCULATIONAHA.117.029190. Go to original source... Go to PubMed...
    11. Neal B, Perkovic V, Mahaffey KV. The CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644- 657. doi: 10.1056/ NEJMoa1611925. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.